Member Info for potnak

I get what Utar is saying. The board delivered value from 0.6p right up to 9p and they did this by engaging the market and shareholders. The £4.5 million of subscriptions really shouldn't have added £200 million to the market cap but yet is did. The value was added because, it felt, that finally we were on the move and going forward. They seemed more confident in raising the profile of the company. Replying to a Boris Johnson tweet even. Then after the last subscription, it seemed to change. We went back to the silence. I hoping as Tim once said that no news is good news.

I think the board will manage the SP back up to the 9p region. We should be happily sitting at 8.25, the last subscription but yes, the market got spooked by a badly written RNS, which the last one had to rectify. I'm glad they didn't clarify the roadmap and dates as it would have set it in stone. Pains me to say it but the vagueness might be holding the SP steady. By the time the AGM comes around and questions will need to be answered, Early 2022 won't sound so bad. My bet is they will use the CTA applications to create interest again. Then maybe another subscription at 9p or more with the patent coming up the rear. 737 is still unknown and could add a penny or 10p, depending on what the news is. As always, we sit and be patient. I think the problem is most new investors are here for a buyout multibagger but the reality is P1 trials for Covid and Immune in 2022. IMO buyout talks will start if we ace P1 tox studies and can we avoid the new FDA black box warnings. That's what the potential partners will want to know. If we can, the potential market is huge. I would say 12p by the end of Oct possibly more if 737 news is good.

Lol, Baserite. Are you ok Hun? DM babe. :-)

If Sierra hand it back,
A: it won't come back to SAR, it will go back to the CRT fund.
B: it will mean that Sierra doesn't see any value in advancing the compound.

And if trading the a r s e off this share is taking a max of £25k out over the years then, I'm guilty as charged. I wish I had sold more at 9p, I could've made my pot bigger I bet you do to. Also, duplicitous? just because I sit on the fence? There is BS on both sides of this fence and no one really knows what is going to happen so I will sit comfortably up here until it is time for my exit.

The fact they don't talk about it, ever. Means there is something to talk about IMO. It's only a matter of time.

I agree that if the HNWI came from Michael Owens address book then the next logical step is the Wellcome Trust funding Sareum further. It would explain why the Covid angle is still unknown too. But I don't believe that the Gates have invested directly, why would they when they can chuck 10 x that in officially. I still reckon the HNWI know the next logical step is big funding so they got in early. Like you said. We will find out soon.

Stating HNWI differentiates between Institutional and private investors. They don't have to name the investor (they would have to if it was an ii). IMO they won't have divulged any insider information to the HNWI. They are like any other private investor but they bought in an orderly way that allows the company to show confidence in their product. The first two subscribers made an instant profit too. I don't believe it is BG or anyone super well known. I reckon it's more likely to be one of Michael Owens chums from his Kymab days maybe even someone who became an HNWI because of Kymab? The Wellcome Trust link is still there if you want to go down that particular rabbit hole.

I'm not sure we will ever know who they are but they helped SAR get to the sort of value we should have been trading at anyway so it's a win for me. I've got a feeling news is near and once it drops the flow will constant, running into 2022.

Stating HNWI differentiates between Institutional and private investors. They don't have to name the investor (they would have to if it was an ii). IMO they won't have divulged any insider information to the HNWI. They are like any other private investor but they bought in an orderly way that allows the company to show confidence in their product. The first two subscribers made an instant profit too. I don't believe it is BG or anyone super well known. I reckon it's more likely to be one of Michael Owens chums from his Kymab days maybe even someone who became an HNWI because of Kymab? The Wellcome Trust link is still there if you want to go down that particular rabbit hole.

I'm not sure we will ever know who they are but they helped SAR get to the sort of value we should have been trading at anyway so it's a win for me. I've got a feeling news is near and once it drops the flow will constant, running into 2022.

I'm not sure what he could tweet, Fearg. We need more TYK2 covid papers that he can retweet saying we got one of these. I'm resigned to the fact that fireworks will now start in 2022. Unless Sierra announces 737 combo trials or even better an on licence to AZN.

Should be loads of news flow as we head into Q4 at the end of this month. I'm not sure which bit of news people are expecting? Covid and Immune have sort of been kicked into next as per the last 2 RNS. I'm not saying it will be next year but they set out expectations by saying trials will begin in 2022. However, for trials to begin in 2022 we will need to files the CTA for Immune and Covid. The usual is 1 month for assessment but It can take 3 or more to get approval. I'd expect them to file for the CTA's in October to give plenty of time. I think we have enough cash to run one P1 but not both so we might get some news on how we will fund the trials. I can't see us getting a buyout offer until all patents are in place or at least registered so no one can copy the invention. Some think the secret patent will be revealed soon and that may cause a stir when it lands. IMO the only news that may come out of the blue is for SRA737 or more subscriptions? I would have like them to reference the FDA warnings on JAKs but I guess, if they are in talks, they can't. The impatient here really need to read the RNS's and think about what they are telling you. They don't write them for fun.

Absolutely.

It isn't TJB's tweet. It's another of our resident LTH and deramp of Sierra, not SAR.

https://twitter.com/sra737PRTeam/status/1435593796163616775?s=20

They are not TJB's words and it means Siera's SP. Regardless of the tweet. There is no way it will come back. They might sell it on to someone else though.

I'm a bit of a geek so can remember all of mine.
ZX81
Atari 2600 console
ZX Spectrum
Nintendo
Amiga 1200
Sega Mega Drive
SNES
Atari ST (for the music production capabilities)
Then went the PC way
386
486 with Turbo button
Pentium 75, this was really a 486 with a dedicated floating-point unit (this bit that does the maths)
I then went over to the AMD chipset for a few iterations
Xbox One
Now back on Intel based kit

We should be sitting at 8.25p at least. Maybe the FDA warning has spooked some investors? The fact we've seen nothing from the company referencing the FDA warning, either way, is a minor concern but how do you comment on this because we have to prove that our TYK2 is cleaner, just like the big boys will have to prove theirs is. We are all back on the start line together. Everything to play for and still a multi-billion pound market, even with the black box warning. I wonder, has anyone here asked Tim to comment on this? Not on Twitter, via email? I suspect you would get a vague answer around we are working with potential partners blah blah. but it might be worth asking anyway.

I never understand the big deal people make about a director buy on an AIM-listed company. YOu are literally saying, the company needs a cash injection and there is no news due. It's usually a trigger to the traders to sell the spike and come back in a month or two. As for the HNW investors. I'm not sure that under the rules they can be given news that we, the other shareholders haven't been given. They are not an institution bound by corporate law and actions. By the very definition, they are an individual with lots of cash. So will they be privy to more info than we are? and if they are, why are they? I think it is more likely that Tim, John and the board have presented the data already known to all of us in a face to face presentation. They will have had all questions answered, straight from the horse's mouth as it we're and none of that would be against the insider trading rules. I really do doubt that they know of any impending news on the horizon. They still invested though and that is good enough for me.

Forget the intraday and weekly prices. Have a strategy at what realistic price you think it will get to and wait for that to come. Based on no news, mine is 3 tranches. 12, 20 and 40p. That may change depending on the order of news.

Drugs get shelved all the time, our own Aurora compound is shelved through lack of funds to develop. The problem with Sierra and 737 is it will take 10's of if not 100's of millions of dollars to push 737 to market. It's a big risk and they don't actually have the funds to do it. I've said this before, If 737 success was nailed on, they would have the funding in an instant but as it stands, much like SAR and our compounds, it isn't nailed on so it's more difficult to convince someone of the worth of the compound. I suspect any partner, including Gilead will want a bigger piece of the pie to commit to funding the compound into P2\P3 trials.

This leads us back to Baliifs question. The reason the SP isn't moving is that there are so many unknowns and at this point in time, the SP is about where it should be. I still think the bottom should be 8.25p though but that is my opinion. :-)

We had a LTH here who sold a load of SAR to buy Sierra. Can't remember who it was though. We used to have some US based Sierra holders lurking on this board as the research done here was better than the actual Sierra boards. Says a lot, if you ask me.

Yes, personally, I do think it could be covid related. Something that differentiates between Immune and respiratory so it can be split if needed. If that is the case we've already do a POC with 1801 so if the patent is for a tweaked 1801 then presumably the POC studies would have to be run again on the tweaked compound. I don't see that is as a problem and it fits with my own thoughts that 1801 immune is a priority (and rightly so, IMO) but the respiratory indication will have all the relevant data and patents lodged for someone to pick up and run with into accelerated trials.